Barclays raised the firm’s price target on Johnson & Johnson to $166 from $159 and keeps an Equal Weight rating on the shares. The company reported solid Q4 results and continues to deliver consistent portfolio growth in Pharma and MedTech, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson-backed medical device company seeks U.S. IPO, Bloomberg says
- Johnson & Johnson price target lowered to $165 from $170 at Raymond James
- Johnson & Johnson price target lowered to $155 from $170 at Stifel
- Johnson & Johnson price target lowered to $159 from $160 at BofA
- Johnson & Johnson price target lowered to $163 from $175 at Morgan Stanley